Rna replicon for improving gene expression and use thereof
US-2024417751-A1 · Dec 19, 2024 · US
US9545453B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9545453-B2 |
| Application number | US-201214351789-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 15, 2012 |
| Priority date | Oct 14, 2011 |
| Publication date | Jan 17, 2017 |
| Grant date | Jan 17, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention generally relates to carriers including polymers and lipids that comprise a CXCR4 inhibiting moiety. More specifically, these carriers are biodegradable and can be bioreducible polymers that comprise a CXCR4 inhibiting moiety. These carriers can be suitable for delivery of nucleic acids to cells. These carriers and pharmaceutical compositions can be used to treat various conditions including cancers and inflammation conditions.
Opening claim text (preview).
The invention claimed is: 1. A polymer comprising structural units of a CXCR4 inhibiting moiety and either (i) a structural unit of Formula 11, (ii) a structural unit of Formula 22, (iii) structural units of Formulae 11 and 22, (iv) structural units of Formulae 11 and 88, (v) structural units of Formulae 22 and 88, (vi) structural units of Formulae 11, 22, and 88, the structural units of Formulae 11, 22, and 88 corresponding to the following structures: wherein X 11 and X 22 are independently —NH—C(O)—CH 2 CH 2 —, —O—C(O)—CH 2 CH 2 —, —C(O)O—, —C(O)—, or —NH—C(O)—; R 12 , R 13 , R 14 , R 15 are independently hydrogen, alkyl, or substituted alkyl; R 88 and R 89 are independently alkyl or substituted alkyl; n 1 is independently an integer from 1 to 4; and n 2 is an integer from 1 to 8, wherein CXCR4 inhibiting moiety is derived from a cyclam compound and the cyclam compound corresponds to Formula 5, wherein Formula 5 corresponds to the following structure: wherein R 1 is —R 8 —NH 2 ; R 2 , R 3 , and R 4 are hydrogen; and R 8 is —CH 2 —C 6 H 4 —CH 2 —N(C(O))t-Bu)-(CH 2 ) 3 —. 2. The polymer of claim 1 wherein the structural unit corresponds to Formula 11. 3. The polymer of claim 2 wherein X 11 is —NH—C(O)—CH 2 CH 2 — and R 12 , R 13 , R 14 , R 15 are hydrogen. 4. The polymer of claim 1 wherein R 12 and R 14 are hydrogen and R 13 and R 15 are —C(O)O-alkyl. 5. The polymer of claim 4 wherein X ii is —NH—C(O)—CH 2 CH 2 — and n 1 is 2. 6. The polymer of claim 1 wherein the structural unit corresponds to Formula 22. 7. The polymer of claim 6 wherein X 22 is —NH—C(O)—CH 2 CH 2 — or —O—C(O)—CH 2 CH 2 —. 8. The polymer of claim 7 wherein X 22 is —NH—C(O)—CH 2 CH 2 — and n 2 is an integer from 4 to 6. 9. The polymer of claim 1 wherein the structural units correspond to Formulae 11 and 22. 10. The polymer of claim 1 comprising a structural unit of Formula 88. 11. The polymer of claim 10 wherein R 88 is methyl and R 89 is 2-hydroxypropyl. 12. The polymer of claim 1 wherein the polymer further comprises an amine structural unit of Formula 33, the amine structural unit of Formula 33 corresponding to the following structure: wherein R 30 is C 2 to C 12 alkylene, arylene, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amine; R 31 and R 32 are independently hydrogen, alkyl or aryl. 13. A polyplex comprising a polymer of claim 1 and a nucleic acid. 14. The polyplex of claim 13 wherein the nucleic acid is plasmid DNA, shRNA, siRNA or microRNA. 15. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a polyplex of claim 13 . 16. The polymer of claim 1 wherein the structural unit corresponds to Formula 11, X 11 is —NH—C(O)—CH 2 CH 2 —, R 12 , R 13 , R 14 , R 15 are independently hydrogen, and n 1 is 2. 17. The polymer of claim 8 wherein n 2 is 6.
Human Necessities · mapped topic
Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation · CPC title
Human Necessities · mapped topic
containing nitrogen · CPC title
Double-stranded nucleic acids or oligonucleotides · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.